Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

@article{Tremlett2004HepaticIL,
  title={Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis},
  author={Helen Tremlett and Jo{\"e}l J. -F. Oger},
  journal={Journal of Neurology},
  year={2004},
  volume={251},
  pages={1297-1303}
}
This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development… 
Hepatic flares induced by disease-modifying treatments in patients with multiple sclerosis
TLDR
Regular testing of ALT, AST, AP and bilirubin, at least monthly for the first six months, then six-monthly thereafter, probably can minimise Type A or dose-dependent reactions and a pre-treatment screen might be useful to eliminate other causes of liver test elevations in patients on treatment with interferon beta.
Acute liver failure in a patient with multiple sclerosis treated with interferon-β
TLDR
An uncommon case of ALF requiring liver transplant occurring five years after starting interferon-b treatment in a patient with multiple sclerosis (MS) is reported, and patients should be frequently monitored in order to detect eventual deterioration of liver function.
Nephrotic Syndrome in a Multiple Sclerosis Patient Treated with Interferon β1a
  • A. Auty, Abdulkarim Saleh
  • Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2005
TLDR
This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.
Drug-induced liver injury
TLDR
Although no pharmacological therapy has been adequately tested in randomized clinical trials, corticosteroids can be useful, particularly in the emergent form of DILI related to immune-checkpoint inhibitors in patients with cancer.
Therapeutic role of beta-interferons in multiple sclerosis.
TLDR
The incomplete resolution of immune dysfunction by IFNs partly explains their significant, but modest therapeutic effects, and suggests that there are immune mechanisms in MS that are resistant to IFN therapy.
Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
TLDR
Pivotal trials, their cross-over extensions, and post-marketing studies consistently showed that INF β 1a 22 or 44 μg s.c.i.w. is safe and well tolerated, as adverse drug reactions are usually mild and manageable.
Interferon-β treatment for multiple sclerosis
TLDR
Although its mechanism of action remains incompletely understood, a reduction in active lesions seen on magnetic resonance imaging implies primary anti-inflammatory properties, a mechanism supported by basic immunologic research.
Interferon-β Fails to Protect in a Model of Transient Focal Stroke
TLDR
Interferon (IFN)-β and PEG-IFN-β failed to protect against experimental ischemic brain injury as assessed by histopathology and neurological outcome, and IFN- β treatment was associated with significant weight loss and alterations in hematology and chemistry profiles.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Fulminant liver failure during interferon beta treatment of multiple sclerosis
TLDR
A patient who developed acute fulminant liver failure a few weeks after the initiation of IFN β and required an emergency liver transplant is reported, the first patient reported who required a liver transplant as a result of MS therapy.
Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
TLDR
Asymptomatic hepatic dysfunction is common in patients with multiple sclerosis who are treated with interferon-beta-1a, and is dose related, and regular liver function monitoring during the first 6 months is recommended.
Serum transaminase elevations as indicators of hepatic injury following the administration of drugs.
  • D. Amacher
  • Medicine
    Regulatory toxicology and pharmacology : RTP
  • 1998
TLDR
Some ancillary methods for early preclinical screening such as in vitro metabolism and toxicity assays, gene and protein expression analysis, and some strategies for enhancing the probability for the early detection of idiosyncratic hepatotoxic responses which are infrequent but significant factors in the safety assessment process are summarized.
Possible mechanisms of elevation of serum transaminase levels during interferon-β therapy in chronic hepatitis C patients
TLDR
Dgenerative, apoptotic, and necrotic changes in hepatocytes, probably a result of the cytotoxic effects of IFN-β, may have contributed to this elevation of ALT levels, but such changes were absent in most of the patients, suggesting that decisions on the discontinuation of IFn-β therapy must be made in accordance with liver histology findings.
Liver injury associated with the &bgr;-interferons for MS: A comparison between the three products
TLDR
A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a IFN-interferon product in British Columbia, Canada between 1995 and 2001 found that all the IFN&bgr;s caused elevated aminotransferase levels compared with pretreatment levels and were higher than reported in clinical trials.
Chemotherapeutic agents and hepatotoxicity.
  • M. Perry
  • Medicine
    Seminars in oncology
  • 1992
TLDR
Baseline evaluation of patients about to undergo chemotherapy should always include liver function tests, and when clinically indicated, hepatic imaging, and the increased use of high-dose regimens with autologous bone marrow or stem-cell support has complicated the picture by revealing toxicities at very high doses that are not observed with conventional doses.
Dantrolene sodium and hepatic injury
TLDR
There is an overrepresentation of women over 35 years and patients with multiple sclerosis in the fatal group compared with the study population as a whole (not statistically significant), and serum bilirubin may be predictive for death.
Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS
TLDR
The frequency of thyroid dysfunction or of autoimmunity showed random and insignificant changes over time, probably not related to IFNB treatment.
Alanine Aminotransferase Levels: What's Normal?
  • M. Kaplan
  • Medicine
    Annals of Internal Medicine
  • 2002
TLDR
Serum ALT levels correlated strongly with BMI and correlated less robustly with serum triglyceride levels and to laboratory indicators of abnormal lipid or carbohydrate metabolism, as well as to sex, and the gain in sensitivity allowed the detection of persons with minimal to mild histologic lesions.
Canadian Association of Gastroenterology Practice Guidelines: evaluation of abnormal liver enzyme tests.
  • G. Minuk
  • Medicine
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 1998
TLDR
These guidelines outline when screening for liver disease would be appropriate and determine which biochemical tests should be used in screening for Liver disease; review second-line tests for when screening tests are positive; outline when referrals to specialists would beappropriate; and review additional testing that specialists might undertake in their evaluation of the patient.
...
1
2
3
4
5
...